Risk of waning humoral responses after inactivated or subunit recombinant SARS-CoV-2 vaccination in patients with chronic diseases: Findings from a prospective observational study in China

作者全名："Li, Hu; Cai, Dachuan; Jiang, Depeng; Li, Xingsheng; Liao, Xiaohui; Liu, Dongfang; Liu, Zuojin; Zhu, Peng; Yin, Guobing; Ming, Jia; Peng, Mingli; Chen, Min; Ling, Ning; Lan, Yinghua; Zhang, Dazhi; Hu, Peng; Ren, Hong"

作者地址："[Li, Hu; Cai, Dachuan; Peng, Mingli; Chen, Min; Ling, Ning; Lan, Yinghua; Zhang, Dazhi; Hu, Peng; Ren, Hong] Chongqing Med Univ, Inst Viral Hepatitis, Affiliated Hosp 2, Key Lab Mol Biol Infect Dis,Minist Educ,Dept Infe, 288 Tianwen Ave, Chongqing 401336, Peoples R China; [Jiang, Depeng] Chongqing Med Univ, Dept Resp & Crit Care Med, Affiliated Hosp 2, Chongqing, Peoples R China; [Li, Xingsheng] Chongqing Med Univ, Dept Gerontol, Affiliated Hosp 2, Chongqing, Peoples R China; [Liao, Xiaohui] Chongqing Med Univ, Dept Nephrol, Affiliated Hosp 2, Chongqing, Peoples R China; [Liu, Dongfang] Chongqing Med Univ, Dept Endocrinol, Affiliated Hosp 2, Chongqing, Peoples R China; [Liu, Zuojin] Chongqing Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 2, Chongqing, Peoples R China; [Zhu, Peng] Chongqing Med Univ, Dept Surg Gastroenterol, Affiliated Hosp 2, Chongqing, Peoples R China; [Yin, Guobing; Ming, Jia] Chongqing Med Univ, Dept Breast & Thyroid Surg, Affiliated Hosp 2, Chongqing, Peoples R China"

通信作者："Hu, P; Ren, H (通讯作者)，Chongqing Med Univ, Inst Viral Hepatitis, Affiliated Hosp 2, Key Lab Mol Biol Infect Dis,Minist Educ,Dept Infe, 288 Tianwen Ave, Chongqing 401336, Peoples R China."

来源：JOURNAL OF MEDICAL VIROLOGY

ESI学科分类：MICROBIOLOGY

WOS号：WOS:000911465200349

JCR分区：Q1

影响因子：6.8

年份：2023

卷号：95

期号：1

开始页：　

结束页：　

文献类型：Article

关键词：COVID-19; humoral responses; SARS-CoV-2; vaccine

摘要："Heterogeneity of antibody responses has been reported in SARS-CoV-2 vaccination recipients with underlying diseases. We investigated the impact of the presence of comorbidities on the humoral response to SARS-CoV-2 vaccination in patients with chronic disease (PWCD) and assessed the effect of the number of comorbidities on the humoral response to vaccination. In this study, neutralizing antibodies (NAbs) and IgG antibodies against the receptor-binding domain (RBD-IgG) were monitored following a full-course vaccination. In total, 1400 PWCD (82.7%, inactivated vaccines; 17.3%, subunit recombinant vaccine) and 245 healthy controls (65.7% inactivated vaccines, 34.3% subunit recombinant vaccine) vaccinated with inactivated or subunit recombinant SARS-CoV-2 vaccines, were included. The seroconversion and antibody levels of the NAbs and RBD-IgG were different in the PWCD group compared with those in the control group. Chronic hepatitis B (odds ratio [OR]: 0.65; 95% confidence interval [CI]: 0.46-0.93), cancer (OR: 0.65; 95% CI: 0.42-0.99), and diabetes (OR: 0.50; 95% CI: 0.28-0.89) were associated with lower seroconversion of NAbs. Chronic kidney disease (OR: 0.29; 95% CI: 0.11-0.76), cancer (OR: 0.38; 95% CI: 0.23-0.62), and diabetes (OR: 0.37; 95% CI: 0.20-0.69) were associated with lower seroconversion of RBD-IgG. Only the presence of autoimmune disease showed significantly lower NAbs and RBD-IgG titers. Patients with most types of chronic diseases showed similar responses to the controls, but humoral responses were still significantly associated with the presence of >= 2 coexisting diseases. Our study suggested that humoral responses following SARS-CoV-2 vaccination are impaired in patients with certain chronic diseases."

基金机构："National Science and Technology Major Project of China [2017ZX10202203-007, 2017ZX10202203-008, 2018ZX10302206-003]; pilot project of clinical cooperation between traditional Chinese and western medicine for significant and complicated diseases of the National Administration of Traditional Chinese Medicine: Hepatic Fibrosis; Kuanren Talents Program of the Second Affiliated Hospital of Chongqing Medical University, National Natural Science Foundation of China [81772198, 81902068]; Natural Science Foundation of Chongqing, China [cstc2020jcyj-msxmX0389]"

基金资助正文："This work is supported by the National Science and Technology Major Project of China (2017ZX10202203-007, 2017ZX10202203-008, 2018ZX10302206-003) and a pilot project of clinical cooperation between traditional Chinese and western medicine for significant and complicated diseases of the National Administration of Traditional Chinese Medicine: Hepatic Fibrosis. We also acknowledge the support of the Kuanren Talents Program of the Second Affiliated Hospital of Chongqing Medical University, National Natural Science Foundation of China (81772198, 81902068), and Natural Science Foundation of Chongqing, China (cstc2020jcyj-msxmX0389)."